United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eisai ltd - lenvatinib mesilate - capsule - 4mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eisai ltd - lenvatinib mesilate - capsule - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eisai ltd - lenvatinib mesilate - capsule - 4mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eisai ltd - lenvatinib mesilate - capsule - 10mg

European Union - English - EMA (European Medicines Agency)

eisai gmbh - lenvatinib mesilate - carcinoma, renal cell - antineoplastic agents - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5.1).in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

Israel - English - Ministry of Health

eisai israel ltd., israel - lenvatinib as mesilate - hard capsule - lenvatinib as mesilate 10 mg - lenvatinib - lenvima is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) thyroid carcinoma (dtc), refractory to radioactive iodine (rai).lenvima is indicated in combination with everolimus for the treatment of adult patients with advanced clear cell renal cell carcinoma (rcc) following one prior vascular endothelial growth factor (vegf)-targeted therapy.lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have received no prior systemic therapy.lenvima, in combination with pembrolizumab, is indicated for the treatment of adult patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum containing therapy and who are not candidates for curative surgery or radiation.lenvima is indicated in combination with pembrolizumab for the first-line treatment of adult patients with advanced rcc.

Israel - English - Ministry of Health

eisai israel ltd., israel - lenvatinib as mesilate - hard capsule - lenvatinib as mesilate 4 mg - lenvatinib - lenvima is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) thyroid carcinoma (dtc), refractory to radioactive iodine (rai).lenvima is indicated in combination with everolimus for the treatment of adult patients with advanced clear cell renal cell carcinoma (rcc) following one prior vascular endothelial growth factor (vegf)-targeted therapy.lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have received no prior systemic therapy.lenvima, in combination with pembrolizumab, is indicated for the treatment of adult patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum containing therapy and who are not candidates for curative surgery or radiation.lenvima is indicated in combination with pembrolizumab for the first-line treatment of adult patients with advanced rcc.

Singapore - English - HSA (Health Sciences Authority)

eisai (singapore) pte. ltd. - lenvatinib mesilate 4.9 mg eqv lenvatinib - capsule - lenvatinib mesilate 4.9 mg eqv lenvatinib 4.0 mg

Singapore - English - HSA (Health Sciences Authority)

eisai (singapore) pte. ltd. - lenvatinib mesilate 12.25 mg eqv lenvatinib - capsule - lenvatinib mesilate 12.25 mg eqv lenvatinib 10.0 mg

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية نيروخ - nairoukh drug store - lenvatinib 4 mg/1 cap - 4 mg/1 cap